NCT04728893 2026-04-13
MK-1026-003
Merck Sharp & Dohme LLC
Phase 2 Recruiting
Clinical Trials
12 trialsNCT04840602 2026-04-13
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07387471 2026-04-13
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
AbbVie
Phase 2 Recruiting
NCT06561347 2026-03-31
ZEBRA
Massachusetts General Hospital
Phase 2 Recruiting
NCT06510491 2026-03-13
Epcoritamab in Previously Treated WM
Beth Israel Deaconess Medical Center
Phase 2 Recruiting
NCT06986174 2025-12-05
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05099471 2025-11-28
VIWA-1
University of Ulm
Phase 2 Recruiting
NCT07231952 2025-11-17
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05190705 2025-05-23
Loncastuximab Tesirine in WM
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05734495 2025-05-11
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05914662 2024-08-28
ZBR
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT03697356 2023-10-06
Ballondor
Kosin University Gospel Hospital
Phase 2 Recruiting